Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal Lymphadenectomy

Domagała‐Kulawik, Joanna; Kwiecień, Iwona; Pankowski, Juliusz; Pasieka-Lis, Monika; Wołosz, Dominika; Zieliński, Marcin

doi:10.1155/2017/5185034

Cited by 10 publications

(8 citation statements)

References 36 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature suggests that the FoxP3:CD3 ratio in the tumor matrix, as well as expression levels of IL-12 and IL-17, is markedly correlated with post-operative recurrence in early lung adenocarcinoma (22)(23)(24). Moreover, the infiltration of numerous immune factors and immunocytes (including neutrophils, macrophages, and lymphocytes) has also been reported to correlate with angiogenesis, cell proliferation, and invasion of this disease (25).…”

Section: Discussionmentioning

confidence: 97%

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma

et al. 2019

View full text Add to dashboard Cite

We investigated the local immune status and its prognostic value in lung adenocarcinoma. In total, 513 lung adenocarcinoma samples from TCGA and ImmPort databases were collected and analyzed. The R package coxph was employed to mine immune-related genes that were significant prognostic indicators using both univariate and multivariate analyses. The R software package glmnet was then used for Lasso Cox regression analysis, and a prognosis prediction model was constructed for lung adenocarcinoma; clusterProfiler was selected for functional gene annotations and KEGG enrichment analysis. Finally, correlations between the RiskScore and clinical features or signaling pathways were established. Sixty-four immune-related genes remarkably correlated with patient prognosis and were further applied. Samples were hierarchically clustered into two subgroups. Accordingly, the LASSO regression algorithm was employed to screen the 14 most representative immune-related genes (PSMD11,

show abstract

Section: Discussionmentioning

confidence: 97%

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Anticancer immune response is to date especially investigated for NSCLC, without regard to histological types. Recently it was reported a significant lower proportion of CD8+ cells and higher FOXP3+/CD8+ ratio in metastatic versus free lymph nodes only in adenocarcinoma, indicating a particular biology of this type of NSCLC [43] . Other authors demonstrated that CD8+ T cell infiltration strongly contributed to a better prognosis in adenocarcinoma when tumor cells retained the expression of classical HLA class I and did not express HLA-E [44] .…”

Section: Prognostic Immune Cells In Lung Cancermentioning

confidence: 95%

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers

Catacchio

Scattone

Silvestris

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths throughout the world. The majority of patients are diagnosed with locally advanced or metastatic disease when surgery, the best curative option, is no longer feasible. Thus, the prognosis of lung cancer remains poor and heterogeneous and new biomarkers are needed. As the immune system plays a pivotal role in cancer, the study of tumor microenvironment, with regard to the immune component, may provide valuable information for a better comprehension of the pathogenesis and progression of the disease. Through a detailed and critical evaluation of the most recent publications on this topic, we provide evidences of the prognostic and predictive significance of immune markers in tumor and in peripheral blood of lung cancer patients: from the landscape of immune cells (macrophages, neutrophils, lymphocytes and natural killer) and their cytokines, to the analysis of immune-checkpoints (PD-L1 and CTLA4), up to the genetic and epigenetic regulation of the immune response (immune gene signatures and miRNA). We also argue about the lights and shadows related to immune marker use in clinical practice, emphasizing on one hand the importance of their assessment in the choice of therapeutic treatment, on the other, the difficulty in their determination and reproducibility of literature data. The following review gives a foundation and a suggestion for future studies investigating tumor immunology in lung cancer.

show abstract

“…Different methods applied do not yield comparable results; the “high” vs. “low” cell number, proportion, expression of the marker is rather subjective. For example, in our studies extrapolation from a quantitative analysis of cell smears was used and cells proportion was counted (76). The other researches apply different methods and reports from results (77, 78).…”

Section: Lung Cancer Immunitymentioning

confidence: 99%

New Frontiers for Molecular Pathology

Domagała‐Kulawik

2019

Front. Med.

Self Cite

View full text Add to dashboard Cite

Lung cancer remains a serious oncological problem worldwide. The delayed diagnosis and a prevalence of advanced stages in up to 70% of cases at recognition are still observed. Thanks to targeted therapies and immunotherapy a significant progress in achieving prolonged survival in some lung cancer patients is reported. A precise histopathological diagnosis, especially the recognition of adenocarcinoma, and a progress in the methods of clinical staging underlie the proper qualification of patients for a tailored therapy. The deep molecular characteristics of lung cancer in liquid biopsy, for example blood, bronchoalveolar lavage fluid (BALF), cell suspension from needle aspirates, are currently available. The molecular characteristic has recently been extended with molecular aberrations of BRAF, KRAS, MET, ERBB2, RET, NTRK next to the well-known EGFR mutations and ALK, ROS-1 relocation. The present paper discusses the usefulness of adequate pathological methods and molecular testing for the identification of a broad spectrum of predictive biomarkers for a molecular-directed lung cancer therapy. Immunotherapy with immune checkpoint inhibitors (ICIs) is approved in the first line therapy of advanced non-small-cell lung cancer. To date only PD-L1 expression on tumor cells has been found to be a marker of response to ICIs. The efficacy of ICIs as well as the susceptibility to immune-related adverse events are highly individual, so immune biomarkers are widely investigated. The candidates for predictive factors for ICIs immunotherapy include cancer cell antigenicity, presence of regulatory/suppressory molecules on cancer cells, cancer stem cells or on exosomes, and, on the other hand, an immune status of the patient. Cancers with high immune infiltration in the tumor milieu, referred to as “hot” tumors, seem to ensure a better response to ICIs than the “cold” ones. BALF analysis may replace cancer tissue examination, which is of limited access in advanced stages, for the recognition of the nature of immune response in the tumor environment. Tumor mutational burden (TMB) was shown to correlate with a good response to ICIs, especially when combined with other anticancer therapies. The present paper demonstrates the results of recent studies on lung cancer characteristics which bring us closer to the definition of useful prognostic/predictive factors.

show abstract

Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal Lymphadenectomy

Cited by 10 publications

References 36 publications

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers

New Frontiers for Molecular Pathology

Contact Info

Product

Resources

About